Eli Lilly and Co
Omicron subvariants are resistant to key antibody treatments, putting people with weak immune systems at risk of Covid
Emerging omicron subvariants are resistant to key antibody treatments for HIV patients, kidney transplant recipients and other immunocompromised people, making them particularly vulnerable to Covid this winter, the White House warned this week. “With some of the new subvariants that are emerging, some of the main tools we’ve had to protect the immunocompromised like Evusheld […]
Read More
Goldman upgrades Biogen, says it’s poised to address early Alzheimer’s market next year
Biogen shares have a lot more potential upside for investors thanks to positive new data around the company’s early Alzheimer’s drug, Goldman Sachs said Wednesday. The firm upgraded Biogen to a buy from neutral and increased its price target on shares to $370, about 35% from where they closed on Tuesday. The upgrade followed the […]
Read More
2 takeaways from our daily meeting: We like health care and staples, Club names in the news
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. Healthcare and staples leading the market Quick mentions: META, DIS, SBUX 1. Health care and consumer staples leading the market Stocks gained on Monday, with health-care and staples stocks leading […]
Read More
These two strategies can help you stay diversified in any kind of stock market
Using correlations and the barbell strategy can help inform trading decisions in any market. Source
Read More
Jim Cramer makes the bull case for consumer goods stocks
CNBC’s Jim Cramer on Wednesday told investors to consider adding shares of well-established consumer packaged-goods companies to their portfolios. “Nobody’s championing what actually works: these old-line consumer packaged-goods names that we all know,” he said. Cramer highlighted three companies’ most recent quarterly results as examples of why investors should have such stocks on their shopping […]
Read More
Biogen’s Alzheimer’s drug could be more competitive than peers, Stifel says in upgrade to buy
Biogen ‘s new Alzheimer’s treatment could lead to even stronger gains for the biotech company going forward, according to Stifel. Analyst Paul Matteis upgraded shares of the biotech company to buy from hold, saying that upcoming data for Alzheimer treatments from competitors Roche and Eli Lilly could show that clinical results for Biogen’s product, lecanemab, […]
Read More
3 takeaways from our daily meeting: Wall Street’s bounce, small buy, reviewing analyst notes
The Investing Club holds its “Morning Meeting” every weekday at 10:20 a.m. ET. Source
Read More
3 takeaways from our daily meeting: Defensive stocks, trimming semis, Meta downgrade
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. The defensives are the only place to be Semis and U.S.-China tensions Quick mentions: META, STZ 1. The defensives are the only place to be Stocks edged down Tuesday, while […]
Read More
A series of mega-blockbuster drugs are on the horizon. How to invest in the trend
Biopharma companies are having more clinical success treating Alzheimer’s disease and obesity and are taking new approaches in oncology, and that’s creating more mega-blockbuster drugs, according to Bank of America. Analyst Geoff Meacham has identified 20 drugs that have the potential to generate $10 billion or more in annual sales by 2030 within the universe […]
Read More
Eli Lilly’s 2022 gains grow to 20% as it lays out plan for possibly the most successful drug ever
Eli Lilly’s obesity treatment tirzepatide has been granted “fast track” status by the Food and Drug Administration, which means it could win approval as early as late 2023. The drug, which was already approved to treat type 2 diabetes under the name Mounjaro in May, has the potential to be a blockbuster, analysts have said. […]
Read More